Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
Inventors
Narain, Niven Rajin • McCook, John Patrick
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12209285-B2
Publication Date
2025-01-28
Expiration Date
Abstract
Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.
Core Innovation
The invention describes administering Coenzyme Q10 (CoQ10) in its oxidized form for treating or preventing an oncological disorder in a human, with CoQ10 maintained in its oxidized form during treatment. It further specifies oxidized CoQ10 with purity between 95% and 100%, and reports that administration results in an increase of CoQ10 in the oxidized form in the human.
The document characterizes oxidized CoQ10 as an environmental influencer, epimetabolic shifter, or epi-shifter that selectively induces apoptosis and cell death in cancer cells while sparing or benefiting normal cells. It reports a pro-oxidant state and modulation of gene expression in apoptosis and cancer biology pathways, including a metabolic shift toward mitochondrial oxidative phosphorylation and away from glycolysis and the Warburg effect.
The mechanistic rationale includes epi-metabolic and bioenergetic shifts, changes in mitochondrial function and oxidative stress-related signaling, and identification of oxidative phosphorylation-related assays and biomarker or target identification approaches. Reported gene-modulation patterns include changes in angiogenesis genes and apoptosis-related genes, and the document also describes increased IDH1 and PDH-E1, decreased ACL, PKM2, and LDH, reduced HIF-1b1 hypoxia signaling, increased SDH subunit B, decreased Bcl-2, and increased Caspase-3.
The document further reports oxidized CoQ10 approaches in an in vivo pancreatic cancer rat model, where intravenous CoQ10 improves survival dose-dependently and improves survival when combined with doxorubicin while mitigating doxorubicin toxicity. It also describes use of CoQ10 biosynthesis "building block" precursors to alter apoptosis and proliferation markers.
Claims Coverage
The claims coverage centers on two independent claims. Across them, the inventive core is administering Coenzyme Q10 in an oxidized form to treat or prevent an oncological disorder in a human, with one claim also requiring a purity range and an increase of oxidized CoQ10 in the human.
Oxidized Coenzyme Q10 administration with defined purity and increased oxidized level
A method for treating or preventing an oncological disorder in a human by administering Coenzyme Q10 in oxidized form with purity between 95% and 100%, wherein administration results in an increase of CoQ10 in the oxidized form in the human.
Maintaining oxidized Coenzyme Q10 during treatment
A method for treating or preventing an oncological disorder in a human comprising administering Coenzyme Q10 such that treatment occurs, wherein Coenzyme Q10 is maintained in its oxidized form during treatment.
The independent claims focus on redox-state control of Coenzyme Q10 during oncological treatment: one claim requires oxidized CoQ10 of 95% to 100% purity and an increase of oxidized CoQ10 levels in the human, while the other requires that the oxidized form is maintained throughout treatment.
Stated Advantages
Selectively inducing apoptosis and cell death in cancer cells while sparing or benefiting normal cells.
Shifting metabolism toward mitochondrial oxidative phosphorylation rather than glycolysis and the Warburg effect.
Improved survival in an in vivo pancreatic cancer rat model, including dose-dependent improvement after intravenous CoQ10.
Improved survival when oxidized CoQ10 is combined with doxorubicin.
Mitigation of doxorubicin toxicity when combined with CoQ10.
Diminishing tumor symptoms, with outcomes described using pathology, CT, MRI, and serum/plasma markers.
Documented Applications
Treatment or prevention of an oncological disorder in a human, including brain cancer.
Use in an in vivo pancreatic cancer rat model, including intravenous CoQ10 alone and in combination with doxorubicin.
Use of CoQ10 biosynthesis "building block" precursors to alter apoptosis and proliferation markers.
Topical treatment using topical CoQ10 creams for tumor symptom diminishment endpoints.
Interested in licensing this patent?